Compare Abeona Therapeutics Inc (ABEO) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | HYG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $81.32 |
52-Week Low | $4.17 | $78.72 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HYG trades at $79.87, up 0.2% today, with a neutral technical signal. The ETF shows consistent dividend distributions, including $0.42 in May 2026. Bond ETF inflows are surging 60% year-over-year as investors seek yield amid market volatility and Fed uncertainty, according to CNBC on June 25, 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
Outlook remains cautious due to interest rate sensitivity and inflation concerns. Risks include potential Fed rate hikes and narrowing market breadth. The high-yield sector faces pressure from bearish bets, but demand for yield provides support. Investors should weigh income stability against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
